Elo Mutual Pension Insurance Co Sells 6,298 Shares of Moderna, Inc. (NASDAQ:MRNA)

Elo Mutual Pension Insurance Co lowered its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 21.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,637 shares of the company’s stock after selling 6,298 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Moderna were worth $941,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. State Street Corp lifted its holdings in shares of Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares during the last quarter. Amundi lifted its stake in shares of Moderna by 79.8% in the 4th quarter. Amundi now owns 1,206,273 shares of the company’s stock valued at $52,075,000 after purchasing an additional 535,273 shares during the last quarter. Two Sigma Advisers LP purchased a new position in shares of Moderna in the 3rd quarter worth approximately $23,825,000. Finally, Douglas Lane & Associates LLC increased its position in shares of Moderna by 62.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after purchasing an additional 298,715 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MRNA. Berenberg Bank raised their price target on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Bank of America dropped their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday, February 11th. UBS Group reduced their price objective on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, February 19th. Citigroup started coverage on Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 target price for the company. Finally, The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $59.00.

Moderna Stock Down 3.1 %

Moderna stock opened at $31.12 on Monday. The firm has a market cap of $12.03 billion, a P/E ratio of -3.35 and a beta of 1.86. The business has a fifty day moving average of $34.72 and a two-hundred day moving average of $44.13. Moderna, Inc. has a twelve month low of $29.25 and a twelve month high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.